['cystic fibrosis']
['tez/iva', 'vx-659', 'iva', 'matched placebos', 'tez', 'vx-561']

        Key Inclusion Criteria:

          -  Body weight ≥35 kg.

          -  Subjects must have an eligibleCFTR genotype.

               -  Part 1 and Part 3: Heterozygous for F508del and an MF mutation (F/MF)

               -  Part 2: Homozygous for F508del (F/F)

          -  FEV1 value ≥40% and ≤90% of predicted mean for age, sex, and height

        Key Exclusion Criteria:

          -  History of clinically significant cirrhosis with or without portal hypertension.

          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency

          -  Lung infection with organisms associated with a more rapid decline in pulmonary
             status.

          -  History of solid organ or hematological transplantation.

        Other protocol defined Inclusion/Exclusion criteria may apply.
      